IBRX · ImmunityBio Inc
United States · RS rating 77 · As of 2026-11-03
| Price | 8.29 USD |
|---|---|
| 1-day change | +4.3% |
| RS rating (overall / 1M / 3M / 12M) | 77 / 21 / 86 / 98 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 44 / 53 / 37 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +14.3% |
| Sales growth Q/Q | +19.4% |
| Distance from 52-week high | +28.2% |
| Market cap (USD) | $8.5B |